Navigation Links
Omnicell Announces Record Revenue and Profit in Third Quarter 2012
Date:10/25/2012

MOUNTAIN VIEW, Calif., Oct. 25, 2012 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions to healthcare systems, today announced results for its quarter ended September 30, 2012, which includes the third quarter results of Omnicell's acquisition of MTS Medication Technologies, Inc. ("MTS") in May 2012.

(Logo: http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a)

GAAP results: Revenue for the third quarter of 2012 was $84.3 million, up $8.9 million or 11.9% from the second quarter of 2012, and up $19.9 million or 30.9% from the third quarter of 2011. Revenue for the nine months ended September 30, 2012 was $223.9 million, up $41.3 million or 22.6% from the nine months ended September 30, 2011.

Third quarter 2012 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $6.9 million, or $0.20 per diluted share. This compares to net income of $1.4 million, or $0.04 per diluted share, in the second quarter of 2012 and net income of $3.0 million, or $0.09 per diluted share, in the third quarter of 2011. For the nine months ended September 30, 2012, net income was $10.6 million, or $0.31 per diluted share. This compares to net income of $6.3 million, or $0.18 per diluted share, for the nine months ended September 30, 2011.

Non-GAAP results: Non-GAAP net income was $9.9 million for the third quarter of 2012, or $0.29 per diluted share. Non-GAAP net income for the third quarter excludes $2.4 million in stock-based compensation expense and the $0.7 million after-tax effect of amortization expense for all intangible assets acquired in connection with the acquisition of MTS completed in May 2012, as well as all earlier Omnicell acquisitions. This compares to non-GAAP net income of $6.7 million, or $0.20 per diluted share, for the second quarter of 2012, which excluded $2.2 million in stock-based compensation expense and the $3.2 million after-tax effect of MTS acquisition costs and amortization expense for all intangible assets acquired in connection with the acquisition as well as all earlier Omnicell acquisitions. Third quarter 2012 results compare to non-GAAP net income of $5.4 million, or $0.16 per diluted share, for the third quarter of 2011, which excluded $2.4 million of stock-based compensation expense.

For the nine months ended September 30, 2012, non-GAAP net income was $21.2 million, or $0.62 per diluted share. This excluded $6.8 million in stock-based compensation expense and the $3.8 million after-tax effect of acquisition costs and amortization expense for all intangible assets acquired in connection with the MTS acquisition as well as all earlier Omnicell acquisitions.

For the nine months ended September 30, 2011, non-GAAP net income was $14.1 million, or $0.41 per diluted share, excluding $7.3 million in stock-based compensation expense and a $1.0 million pre-tax settlement expense for litigation claims.

"Our performance in the third quarter of 2012 demonstrates that our three-part strategy of expanding in the U.S., making selective acquisitions, and achieving targeted international expansion is driving growth in revenue and profits," said Randall Lipps, Omnicell president, chairman and CEO. "We continue to see strong competitive conversion momentum in our Acute Care business and the profit generated by our Non-Acute Care segment, following the acquisition of MTS, is ahead of our earlier projections, as multi-medication adherence packaging is entering new markets outside the U.S."

"I am particularly pleased that we achieved record operating margin in the third quarter, meeting our goal earlier than projected, even while continuing to invest in our product line and market strategies," Mr. Lipps added.

Omnicell Conference Call Information
Omnicell will hold a conference call today at 2:30 p.m. PT to discuss third quarter financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 47024941. Internet users can access the conference call at http://ir.omnicell.com/events.cfm. A replay of the call will be available today at approximately 3:30 p.m. PT and will be available until 8:59 p.m. PT on November 1. The replay access numbers are 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, conference code # 47024941.

About Omnicell 
Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of automation and business information solutions enabling hospitals and other healthcare organizations to streamline the medication administration process and manage costly medical supplies for increased operational efficiency and enhanced patient safety. Through seamless integration with a customer's existing IT infrastructure, Omnicell solutions empower healthcare facilities to achieve comprehensive automation of medication and supply management from the arrival at the loading dock to the patient's bedside. Omnicell also provides healthcare facilities with business analytics software designed to improve medication diversion detection and regulatory compliance.

Since 1992, more than 2,600 hospital customers worldwide have utilized Omnicell's medication automation, supply chain, and analytics solutions to enable them to increase patient safety, improve efficiency and address changing healthcare regulations while providing effective control of costs, charge capture for payer reimbursement and inventory management of medications and supplies.

MTS Medication Technologies, a wholly-owned Omnicell subsidiary, is a leader in medication adherence packaging systems designed to improve medication dispensing and administration. MTS enables approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards while optimizing productivity and controlling costs. The MTS product line includes more than 20 packaging machines and 50 types of consumable products.

For more information about Omnicell, please visit www.omnicell.com. Visit www.mts-mt.com for more information about MTS.

Forward-Looking Statements
To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company's Securities and Exchange Commission (SEC) filings and include, without limitation, our ability to successfully integrate MTS and avoid disruptions in our business, the potential failure to realize the anticipated benefits of the MTS acquisition, unfavorable general economic and market conditions, risks to growth and acceptance of our products and services and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, and the ability of the company to improve sales productivity to grow product backlog, retain key personnel, to cut expenses, to manage future changes in revenue levels, to develop new products and integrate acquired companies, products or intellectual property in a timely and cost-effective manner. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share. Additionally, we calculate Adjusted EBITDA (another non-GAAP measure) by means of adjustments to GAAP Net Income. These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, net income per diluted share, or any other performance measure derived in accordance with GAAP. We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP net income per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a) Stock-based compensation expense impact of Accounting Standards Codification (ASC) 718. We recognize equity plan-related compensation expenses, which represent the fair value of all share-based payments to employees, including grants of employee stock options, as required under ASC 718, "Stock Compensation" as non-GAAP adjustments in each period.

b) Litigation settlement (net of tax). We recorded an accrual in the first quarter of 2011 for settlement of litigation claims for $1.0 million ($0.6 million net of the $0.4 million income tax effect). This charge is not expected to be recurring and, as such, the financial impact is excluded from our non-GAAP results.

c) Acquisition-related transaction and integration expenses. In connection with our acquisition of MTS, we recorded $4.9 million of acquisition transaction and integration costs ($2.9 million net of the $2.0 million tax effect) in the second quarter of 2012. This charge is not expected to be recurring and, as such, the financial impact is excluded from our non-GAAP results.

d) Intangible assets amortization from business acquisitions. Beginning in the second quarter of 2012 (without revising prior periods), we are also excluding from our non-GAAP results the amortization expense resulting from the MTS acquisition as well as earlier Omnicell acquisitions. This impacts the second quarter and third quarter non-GAAP results by $0.5 million ($0.3 million net of the $0.2 million tax effect) and $1.1 million ($0.7 million net of the $0.4 million tax effect), respectively. The September 30, 2012 year-to-date non-GAAP results are affected by $1.6 million ($1.0 million net of $0.6 million tax effect). These non-cash charges, as considered by management, are not reflecting the core cash-generating performance of the business and therefore are excluded from our non-GAAP results.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why share-based compensation expense related to ASC 718 is excluded from our non-GAAP financial measures:

i) While share-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present ASC 718 share-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of share-based compensation, under ASC 718 are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options. As a result of these timing and market uncertainties the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

Our Adjusted EBITDA calculation is defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including ASC 718 stock compensation expense. In addition, we are excluding the transaction and integration costs from the May 2012 MTS acquisition from the results for the nine months ended September 30, 2012.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results. In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

  • Omnicell's stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell's GAAP results for the foreseeable future under ASC 718.
  • Other companies, including companies in Omnicell's industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.
  • Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.

    OMCL-E 

    Omnicell, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data, unaudited) Three Months EndedNine Months EndedSeptember 30,
    2012June 30,
    2012September 30,
    2011September 30,
    2012September 30,
    2011Revenues:Product$

    67,446$

    59,269$

    49,790$

    175,239$

    138,583Services and other revenues16,88516,11514,64948,61944,021Total revenue84,33175,38464,439223,858182,604Cost of revenues:Cost of product revenues30,63628,60022,42979,53259,995Cost of services and other revenues7,6087,4087,56223,11422,704Total cost of revenues38,24436,00829,991102,64682,699Gross profit46,08739,37634,448121,21299,905Operating expenses:Research and development5,5455,4996,01917,53816,139Selling, general, and administrative29,31631,44623,63586,38273,713Total operating expenses34,86136,94529,654103,92089,852Income from operations11,2262,4314,79417,29210,053Other income and (expense), net34(73)(191)57(66)Income before provision for income taxes11,2602,3584,60317,3499,987Provision for income taxes4,3409831,6096,7033,736Net income $

    6,920$

    1,375$

    2,994$

    10,646$

    6,251Net income per share:Basic$

    0.21$

    0.04$

    0.09$

    0.32$

    0.19Diluted$

    0.20$

    0.04$

    0.09$

    0.31$

    0.18Weighted average shares outstanding:Basic33,19333,39033,20933,31633,132Diluted34,06834,31634,21934,24134,100 

    Omnicell, Inc.Condensed Consolidated Balance Sheets(In thousands) September 30,December 31,20122011(unaudited)(1)ASSETSCurrent assets:Cash and cash equivalents$

    54,818$

    191,762Short-term investments—8,107Accounts receivable, net53,10938,661Inventories26,40018,107Prepaid expenses13,94810,495Deferred tax assets11,19710,352Other current assets7,0466,107Total current assets166,518283,591Property and equipment, net32,18517,306Non-current net investment in sales-type leases10,6288,785Goodwill112,68328,543Other intangible assets86,2344,231Non-current deferred tax assets—11,677Other assets13,7549,716Total assets$

    422,002$

    363,849LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$

    18,635$

    11,000Accrued compensation8,1307,328Accrued liabilities12,2068,901Deferred service revenue19,99419,191Deferred gross profit19,58714,210Total current liabilities78,55260,630Non-current deferred service revenue19,64918,966Non-current deferred tax liabilities21,575—Other long-term liabilities5,7131,339Total liabilities125,48980,935Stockholders' equity:Total stockholders' equity296,513282,914Total liabilities and stockholders' equity$

    422,002$

    363,849(1) Information derived from our December 31, 2011 audited Consolidated Financial Statements. 

     

    Omnicell, Inc.Reconciliation of GAAP to Non-GAAP(In thousands, except per share data, unaudited) Three Months EndedSeptember 30, 2012June 30, 2012September 30, 2011Net
    incomeNet income
    per share-
    dilutedNet
    incomeNet income
    per share-
    dilutedNet
    incomeNet income
    per share-
    dilutedGAAP$

    6,920$

    0.20$

    1,375$

    0.04$

    2,994$

    0.09Non-GAAP adjustments:Business acquisition costsTransaction and integration costs for acquisitions (a)—4,855—Amortization of intangible assets acquired by acquisition (b)1,057558—Subtotal pretax adjustments 1,0575,413—Income tax effect of  non-GAAP adjustments (c) (407)(2,256)—Subtotal after-tax adjustments6503,157—ASC 718 share-based compensation adjustment (d)Gross profit275233358Operating expenses2,0861,9802,053Total after-tax adjustments3,0110.095,3700.162,4110.07Non-GAAP$

    9,931$

    0.29$

    6,745$

    0.20$

    5,405$

    0.16(a) This adjustment is for the incurrence of transaction and integration costs related to our acquisition of MTS in May 2012.(b) Beginning with the second quarter of 2012, we are recognizing the amortization expense resulting from all intangible assets recorded from business acquisitions as a non-GAAP adjustment, including MTS and prior acquisitions.(c) Tax effects are calculated using the effective tax rates for the respective periods presented.(d) This adjustment reflects the accounting impact of non-cash stock-based compensation expense related to the impact of ASC 718 for the periods shown. 

    Omnicell, Inc.Reconciliation of GAAP to Non-GAAP(In thousands, except per share data, unaudited) Nine Months EndedSeptember 30, 2012September 30, 2011Net
    incomeNet income
    per share-
    dilutedNet
    incomeNet income
    per share-
    dilutedGAAP$

    10,646$

    0.31$

    6,251$

    0.18Non-GAAP adjustments:Business acquisition costsTransaction and integration costs for acquisitions (a)4,855Amortization of intangible assets acquired by acquisition (b)1,615Litigation settlement (c)—1,000Subtotal pretax adjustments6,4701,000Income tax effect of  non-GAAP adjustments (d)(2,663)(380)Subtotal after-tax adjustments3,807620ASC 718 share-based compensation adjustment (e)Gross profit7761,108Operating expenses6,0056,146Total after tax adjustments10,5880.317,8740.23Non-GAAP$

    21,234$

    0.62$

    14,125$

    0.41(a) This adjustment is for the incurrence of transaction and integration costs related to our acquisition of MTS in May 2012.(b) Beginning with the second quarter of 2012, we are recognizing the amortization expense resulting from all intangible assets recorded from business acquisitions as a non-GAAP adjustment, including MTS and prior acquisitions.(c) This adjustment is for the accrual of a $1.0 million pre-tax settlement in operating expenses ($0.6 million, net of tax effect of $0.4 million) in the first quarter of 2011.(d) Tax effects are calculated using the effective tax rates for the respective periods presented.(e) This adjustment reflects the accounting impact of non-cash stock-based compensation expense related to the impact of ASC 718 for the periods shown. 

    Omnicell, Inc.Calculation of Adjusted EBITDA (1)(In thousands, unaudited) Three Months EndedNine Months EndedSeptember 30,2012June 30,
    2012September 30, 2011September 30, 2012September 30, 2011GAAP net income $

    6,920$

    1,375$

    2,994$

    10,646$

    6,251Add back:ASC 718 stock compensation expense2,3612,2132,4116,7817,254Transaction and integration costs for acquisitions, pre-tax —4,855—4,855—Litigation settlement, pre-tax————1,000Interest9(24)(34)(46)(184)Depreciation and amortization expense3,9132,9982,0279,2465,821Income tax expense4,3409831,6096,7033,736Non-GAAP adjusted EBITDA (1)$

    17,543$

    12,400$

    9,007$

    38,185$

    23,878(1) Defined as earnings before interest income and expense, taxes, depreciation and amortization, and non-cash expenses, including stock compensation expense, per ASC 718, as well excluding certain non-GAAP adjustments. The non-GAAP adjustments for the three months ended June 30, 2012 and the nine months ended September 30, 2012 also exclude transaction and integration costs for MTS, acquired in May 2012. The non-GAAP adjustments for the three months ended June 30, 2012 and the nine months ended September 30, 2012 also exclude transaction and integration costs for MTS, acquired in May 2012. The non-GAAP adjustments for the nine months ended September 30, 2011 also exclude first quarter 2011 expense for a pre-tax litigation settlement. 

     

     


    '/>"/>
    SOURCE Omnicell, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Omnicell To Present At Think Equitys 9th Annual Growth Conference: G9
    2. Omnicell Announces Second Quarter 2012 Results
    3. University of South Alabama Health System Selects Omnicell G4 Solutions
    4. Omnicell to Release Second Quarter 2012 Earnings Results on August 1
    5. Omnicell Repeats Best in KLAS Award for OmniRx Automated Medication Dispensing System
    6. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
    7. Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results
    8. IRIDEX Announces Third Quarter 2012 Conference Call and Release Date
    9. PDI, Inc. Announces New Multi-Year Win Valued At up to $150 Million and Provides Outlook for 2012
    10. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
    11. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/26/2016)... , May 26, 2016 Since ... matured into an essential life science tool for conducting ... applications. BCC Research reveals in its new report that ... growth phase, one powered by a range of new ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
    (Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
    (Date:5/25/2016)... 25, 2016 According to a ... (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), ... (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to 2021", ... Animation Market for the forecast period of 2016 to ... Million by 2021 from USD 117.3 Million in 2016, ...
    Breaking Medicine Technology:
    (Date:5/26/2016)... NJ (PRWEB) , ... May 26, 2016 , ... ... recognized as an NJ Top Doc! Along with his wonderful accolades and stellar ... in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is a highly ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, ... the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led ... professional through the 8 hour interactive course to qualify participants as certified PowerWave ...
    (Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
    (Date:5/26/2016)... ... May 26, 2016 , ... OncLive® , a ... Cancer Institute-designated University of Virginia (UVA) Cancer Center to its quickly ... and marketing teams will publicize and promote public awareness of UVA Cancer Center’s ...
    (Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National Eye ... and international water advocate, was honored by Ashram, Inc. as the world’s foremost water ... knelt on the banks of the Nile to fill their red clay pots with ...
    Breaking Medicine News(10 mins):